

REMARKS:

The Examiner has required restriction of the Examination of the above-identified application, under 35 U.S.C. 121.

The Applicants elect the subject matter of Group I, as identified in the Office Action of August 13, 2004, with traverse. The Examiner has not indicated why the prosecution of all claims in the application presents a serious burden for prosecution. The previous applications, of which this present application is a continuation, have been searched and examined without a restriction requirement prior to search. While the Applicants seek to claim subject matter in the present application which is novel and non-obvious over the previous parent filings, the scope of the invention subject matter in the present application represents a similar type of scope of invention subject matter as in the parent filings which required no restriction. Therefore, the Applicants do not believe that a search for all of the claimed subject matter in the present application represents a serious burden for the Examiner. Applicants, therefore, respectfully request that the Examiner withdraw the present restriction requirement.


Alternatively, Applicants herein reserve their right to elect prosecution of the remaining species and claims for further prosecution in the future.

Applicants respectfully request entry of this amendment and favorable consideration of the claims in light thereof. The Examiner is authorized to charge any additional fees which may be due under 37 C.F.R. 1.17 or credit any overpayment to Account No. 19-0134 in the name of Novartis Corporation.

If it will advance prosecution of this matter the Examiner is encouraged to contact the Applicants' undersigned counsel at the phone number listed below.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7960


Edward J. Wilusz, Jr.
Attorney for Applicants
Reg. No. 52,370

Date: December 13, 2004